Long Non-Coding RNA PANTR1 is Associated with Poor Prognosis and Influences Angiogenesis and Apoptosis in Clear-Cell Renal Cell Cancer.

Linc-POU3F3 Linc01158 PANTR1 clear-cell renal cell carcinoma long intergenic non-coding RNA oncogene renal cell cancer siRNA

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
10 May 2020
Historique:
received: 30 03 2020
revised: 05 05 2020
accepted: 07 05 2020
entrez: 14 5 2020
pubmed: 14 5 2020
medline: 14 5 2020
Statut: epublish

Résumé

POU3F3 adjacent non-coding transcript 1 (PANTR1) is an oncogenic long non-coding RNA with significant influence on numerous cellular features in different types of cancer. No characterization of its role in renal cell carcinoma (RCC) is yet available. In this study, PANTR1 expression was confined to human brain and kidney tissue and was found significantly up-regulated in clear-cell renal cell carcinoma tissue (ccRCC) compared to non-cancerous kidney tissue in two independent cohorts (

Identifiants

pubmed: 32397610
pii: cancers12051200
doi: 10.3390/cancers12051200
pmc: PMC7281347
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Austrian Science Fund
ID : T 1112-B
Organisme : Austrian Society of Urology and Andrology
ID : Richard-Uebelhoer-Grant
Organisme : Horizon 2020
ID : N/A
Organisme : Marie Skłodowska-Curie
ID : grant agreement No 824036
Organisme : Czech Ministry of Health
ID : NV18-03-00554

Références

Gastroenterology. 2014 Jun;146(7):1714-26.e5
pubmed: 24631494
Int J Mol Sci. 2018 Feb 14;19(2):
pubmed: 29443889
Cancer. 2013 Aug 15;119(16):2999-3006
pubmed: 23696129
Int J Mol Sci. 2016 Apr 15;17(4):573
pubmed: 27092491
J Cell Biochem. 2018 Nov 26;:
pubmed: 30474879
Cancer Res. 2014 Sep 1;74(17):4796-810
pubmed: 24962026
Biosci Biotechnol Biochem. 2019 Jun;83(6):1117-1123
pubmed: 30843771
J Urol. 2012 Mar;187(3):834-9
pubmed: 22245331
Anticancer Drugs. 2016 Jun;27(5):383-97
pubmed: 26886011
Mol Cancer. 2015 Jan 21;14:3
pubmed: 25608466
Cancers (Basel). 2019 Oct 17;11(10):
pubmed: 31627266
Int Urol Nephrol. 2012 Aug;44(4):997-1004
pubmed: 22456765
Clin Cancer Res. 2001 Apr;7(4):896-900
pubmed: 11309339
Biomed Pharmacother. 2019 Sep;117:109133
pubmed: 31252264
Am J Transl Res. 2019 Jul 15;11(7):4481-4490
pubmed: 31396351
Mol Cell Proteomics. 2014 Feb;13(2):397-406
pubmed: 24309898
Med Res Rev. 2013 May;33(3):517-53
pubmed: 22318902
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Histopathology. 2013 Jan;62(2):237-46
pubmed: 23020176
J Intern Med. 2013 Feb;273(2):114-27
pubmed: 23216836
Am J Hum Genet. 2019 Aug 1;105(2):403-412
pubmed: 31303265
Eur Rev Med Pharmacol Sci. 2017 Mar;21(5):959-972
pubmed: 28338200
Eur Urol. 2014 Jun;65(6):1140-51
pubmed: 24373479
Elife. 2013 Dec 31;2:e01749
pubmed: 24381249
Toxicol Appl Pharmacol. 2014 Aug 1;278(3):249-58
pubmed: 24823293
Br J Cancer. 2013 Mar 5;108(4):901-7
pubmed: 23385728
Oncotarget. 2016 Jan 5;7(1):961-75
pubmed: 26510906
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
J Clin Endocrinol Metab. 2014 Jan;99(1):E62-72
pubmed: 24170107
Histopathology. 2013 Jan;62(2):219-28
pubmed: 22957986
Clin Cancer Res. 2020 Feb 15;26(4):793-803
pubmed: 31727677
Biomed Pharmacother. 2018 Sep;105:683-689
pubmed: 29906746
Int J Mol Sci. 2017 Nov 22;18(11):
pubmed: 29165391
Oncogene. 2015 Sep 24;34(39):5003-11
pubmed: 25619839
Semin Cancer Biol. 2013 Feb;23(1):18-25
pubmed: 22705278
J Clin Pathol. 2012 Aug;65(8):721-4
pubmed: 22639409
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
Am J Pathol. 2019 Aug;189(8):1637-1653
pubmed: 31345467
Life Sci. 2019 Sep 1;232:116648
pubmed: 31301414
Acta Pharm Sin B. 2015 Sep;5(5):378-89
pubmed: 26579469
Oncotarget. 2018 Feb 14;9(21):15512-15525
pubmed: 29643989
Br J Cancer. 2013 Sep 3;109(5):1123-9
pubmed: 23922109
Cancer Cell Int. 2019 Aug 23;19:221
pubmed: 31462894
Circ Res. 2007 Mar 30;100(6):782-94
pubmed: 17395884
Oncogene. 2011 Apr 21;30(16):1956-62
pubmed: 21151178
Mol Syndromol. 2014 Jan;5(1):32-5
pubmed: 24550763
Eur Urol. 2019 May;75(5):799-810
pubmed: 30803729
J Urol. 2017 Dec;198(6):1247-1252
pubmed: 28716649
Cancer Res. 1993 Sep 1;53(17):3976-85
pubmed: 8358726
Eur Urol. 2017 Mar;71(3):426-436
pubmed: 27939075
World J Urol. 2018 Dec;36(12):1943-1952
pubmed: 29713755
Development. 2003 Oct;130(19):4751-9
pubmed: 12925600
Philos Trans R Soc Lond B Biol Sci. 2018 Jun 5;373(1748):
pubmed: 29685978
EMBO J. 2017 Apr 13;36(8):981-994
pubmed: 28167697
Gene. 2015 Jan 1;554(1):114-9
pubmed: 25445282
PLoS One. 2016 Mar 22;11(3):e0150472
pubmed: 27003440
Genomics Proteomics Bioinformatics. 2016 Feb;14(1):42-54
pubmed: 26883671
Am J Transl Res. 2015 Nov 15;7(11):2262-9
pubmed: 26807174
Tumour Biol. 2017 Jun;39(6):1010428317705849
pubmed: 28653882
Biosci Rep. 2019 Jan 25;39(1):
pubmed: 30602452

Auteurs

Maximilian Seles (M)

Department of Urology, Medical University of Graz, 8036 Graz, Austria.

Georg C Hutterer (GC)

Department of Urology, Medical University of Graz, 8036 Graz, Austria.

Johannes Foßelteder (J)

Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
"Non-coding RNAs and Genome Editing in Cancer" Research Unit, Medical University of Graz, 8036 Graz, Austria.

Marek Svoboda (M)

Central European Institute of Technology (CEITEC), Masaryk University, 62500 Brno, Czech Republic.

Margit Resel (M)

Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
"Non-coding RNAs and Genome Editing in Cancer" Research Unit, Medical University of Graz, 8036 Graz, Austria.

Dominik A Barth (DA)

Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
"Non-coding RNAs and Genome Editing in Cancer" Research Unit, Medical University of Graz, 8036 Graz, Austria.
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Renate Pichler (R)

Department of Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Thomas Bauernhofer (T)

Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.

Richard E Zigeuner (RE)

Department of Urology, Medical University of Graz, 8036 Graz, Austria.

Karl Pummer (K)

Department of Urology, Medical University of Graz, 8036 Graz, Austria.

Ondrej Slaby (O)

Central European Institute of Technology (CEITEC), Masaryk University, 62500 Brno, Czech Republic.
Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic.

Christiane Klec (C)

Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
"Non-coding RNAs and Genome Editing in Cancer" Research Unit, Medical University of Graz, 8036 Graz, Austria.

Martin Pichler (M)

Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
"Non-coding RNAs and Genome Editing in Cancer" Research Unit, Medical University of Graz, 8036 Graz, Austria.
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Classifications MeSH